SVR in ITT patients stratified by JAK2V617F allele burden. Waterfall plots for SVR at 24 weeks stratified by JAK2V617F status and allele burden in patients treated with pacritinib (A) and BAT (B) by ITT analysis. Pacritinib produced SVRs irrespective of JAK2V617F allele burden whereas patients who received BAT (including ruxolitinib) had spleen reduction only in the higher JAK2V617F quartiles. *A patient who received ruxolitinib. SPV, spleen volume.